National Institute of Allergy and Infectious Diseases (NIAID)
2 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Phase 1 study of an mRNA-based cell therapy in chronic granulomatous disease with feasibility and safety as primary outcomes; no results reported in this registry record.
This is a Phase 1 clinical trial registry record with no results posted; it describes a planned study to assess safety and infectivity of a P. vivax challenge agent in healthy adults.